NICE Recommends Chugai Pharmaceutical's Nemluvio for Moderate-to-Severe Atopic Dermatitis in Ages 12 and Above

MT Newswires Live

Jul 02

National Institute for Health and Care Excellence (NICE) has recommended Chugai Pharmaceutical's (TOKYO: 4519) Nemluvio (nemolizumab) for treating moderate-to-severe atopic dermatitis in patients aged 12 and over.

In NICE guidance published on July 2, the regulator cited the treatment's potential to address clinical needs and optimize NHS resources.

The decision follows two-year interim data from Galderma's ARCADIA extension study, presented at the Revolutionizing Atopic Dermatitis Conference, demonstrating the drug's long-term efficacy as an anti-IL-31 receptor A monoclonal antibody.

Chugai developed Nemluvio, while Galderma handles global clinical development and commercialization outside Japan, according to a statement on Chugai's website.

NICE is a UK-based non-departmental public body of the Department of Health and Social Care.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2548600898"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548600898\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2548600898?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-02 17:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548600898","market":"us","top_or_hot":-1,"title":"NICE Recommends Chugai Pharmaceutical's Nemluvio for Moderate-to-Severe Atopic Dermatitis in Ages 12 and Above","media":"MT Newswires Live","content":"<html><body><p> National Institute for Health and Care Excellence (NICE) has recommended Chugai Pharmaceutical's (TOKYO: 4519) Nemluvio (nemolizumab) for treating moderate-to-severe atopic dermatitis in patients aged 12 and over.</p><p>In NICE guidance published on July 2, the regulator cited the treatment's potential to address clinical needs and optimize NHS resources.</p><p>The decision follows two-year interim data from Galderma's ARCADIA extension study, presented at the Revolutionizing Atopic Dermatitis Conference, demonstrating the drug's long-term efficacy as an anti-IL-31 receptor A monoclonal antibody.</p><p>Chugai developed Nemluvio, while Galderma handles global clinical development and commercialization outside Japan, according to a statement on Chugai's website.</p><p>NICE is a UK-based non-departmental public body of the Department of Health and Social Care.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NICE Recommends Chugai Pharmaceutical's Nemluvio for Moderate-to-Severe Atopic Dermatitis in Ages 12 and Above</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNICE Recommends Chugai Pharmaceutical's Nemluvio for Moderate-to-Severe Atopic Dermatitis in Ages 12 and Above\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-07-02 17:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> National Institute for Health and Care Excellence (NICE) has recommended Chugai Pharmaceutical's (TOKYO: 4519) Nemluvio (nemolizumab) for treating moderate-to-severe atopic dermatitis in patients aged 12 and over.</p><p>In NICE guidance published on July 2, the regulator cited the treatment's potential to address clinical needs and optimize NHS resources.</p><p>The decision follows two-year interim data from Galderma's ARCADIA extension study, presented at the Revolutionizing Atopic Dermatitis Conference, demonstrating the drug's long-term efficacy as an anti-IL-31 receptor A monoclonal antibody.</p><p>Chugai developed Nemluvio, while Galderma handles global clinical development and commercialization outside Japan, according to a statement on Chugai's website.</p><p>NICE is a UK-based non-departmental public body of the Department of Health and Social Care.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BFMHRM44.USD","symbol_name":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2548600898","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548600898","pubTimestamp":1751449713,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"National Institute for Health and Care Excellence  has recommended Chugai Pharmaceutical's  Nemluvio  for treating moderate-to-severe atopic dermatitis in patients aged 12 and over.In NICE guidance published on July 2, the regulator cited the treatment's potential to address clinical needs and optimize NHS resources.The decision follows two-year interim data from Galderma's ARCADIA extension study, presented at the Revolutionizing Atopic Dermatitis Conference, demonstrating the drug's long-term efficacy as an anti-IL-31 receptor A monoclonal antibody.Chugai developed Nemluvio, while Galderma handles global clinical development and commercialization outside Japan, according to a statement on Chugai's website.NICE is a UK-based non-departmental public body of the Department of Health and Social Care.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","BK4023":"应用软件","NICE":"NICE系统","BK4543":"AI","BK4566":"资本集团"},"translate_title":"NICE推荐中外制药的Nemluvio治疗12岁及以上中重度特应性皮炎","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NICE":1},"content_text":"National Institute for Health and Care Excellence (NICE) has recommended Chugai Pharmaceutical's (TOKYO: 4519) Nemluvio (nemolizumab) for treating moderate-to-severe atopic dermatitis in patients aged 12 and over.In NICE guidance published on July 2, the regulator cited the treatment's potential to address clinical needs and optimize NHS resources.The decision follows two-year interim data from Galderma's ARCADIA extension study, presented at the Revolutionizing Atopic Dermatitis Conference, demonstrating the drug's long-term efficacy as an anti-IL-31 receptor A monoclonal antibody.Chugai developed Nemluvio, while Galderma handles global clinical development and commercialization outside Japan, according to a statement on Chugai's website.NICE is a UK-based non-departmental public body of the Department of Health and Social Care.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}